bluebird bio Inc (bluebird bio) develops and commercializes gene therapies for the treatment of severe genetic diseases and cancer. The company develops its products based on its integrated product platforms comprising gene therapy, cancer immunotherapy and gene editing.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s R&D focuses on the development of betibeglogene autotemcel, elivaldogene autotemcel, and lovo-cel for SCD. It also focuses on the research and discovery of product candidates using its gene editing technology platform. In FY2022, the company spent US$$240.8 million and has 199 employees working on its R&D activities. As of March 8, 2023, the company has eight U.S. patents, seven patent for drug product manufacturing and LVV, 115 patents and 21 patents or five patents issued by U.S. patents related to LVV platform. The company also entered into Research Development Foundation (RDF) for 31 U.S. and foreign patents and patent applications.